AMGN
Price
$283.64
Change
+$3.54 (+1.26%)
Updated
Sep 5 closing price
Capitalization
150.8B
53 days until earnings call
NVS
Price
$129.74
Change
+$1.32 (+1.03%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
250.37B
53 days until earnings call
Interact to see
Advertisement

AMGN vs NVS

Header iconAMGN vs NVS Comparison
Open Charts AMGN vs NVSBanner chart's image
Amgen
Price$283.64
Change+$3.54 (+1.26%)
Volume$2.3M
Capitalization150.8B
Novartis AG
Price$129.74
Change+$1.32 (+1.03%)
Volume$6.14K
Capitalization250.37B
AMGN vs NVS Comparison Chart in %
Loading...
AMGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AMGN vs. NVS commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Buy and NVS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (AMGN: $283.64 vs. NVS: $128.42)
Brand notoriety: AMGN: Notable vs. NVS: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: AMGN: 120% vs. NVS: 93%
Market capitalization -- AMGN: $150.8B vs. NVS: $250.37B
AMGN [@Pharmaceuticals: Major] is valued at $150.8B. NVS’s [@Pharmaceuticals: Major] market capitalization is $250.37B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $651.91B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $90.72B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMGN’s FA Score shows that 2 FA rating(s) are green whileNVS’s FA Score has 3 green FA rating(s).

  • AMGN’s FA Score: 2 green, 3 red.
  • NVS’s FA Score: 3 green, 2 red.
According to our system of comparison, NVS is a better buy in the long-term than AMGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMGN’s TA Score shows that 4 TA indicator(s) are bullish while NVS’s TA Score has 6 bullish TA indicator(s).

  • AMGN’s TA Score: 4 bullish, 5 bearish.
  • NVS’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, NVS is a better buy in the short-term than AMGN.

Price Growth

AMGN (@Pharmaceuticals: Major) experienced а -1.41% price change this week, while NVS (@Pharmaceuticals: Major) price change was +1.54% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.16%. For the same industry, the average monthly price growth was +3.97%, and the average quarterly price growth was +10.41%.

Reported Earning Dates

AMGN is expected to report earnings on Oct 29, 2025.

NVS is expected to report earnings on Oct 28, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+1.16% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVS($250B) has a higher market cap than AMGN($151B). AMGN has higher P/E ratio than NVS: AMGN (22.90) vs NVS (18.72). NVS YTD gains are higher at: 36.721 vs. AMGN (12.147). NVS has higher annual earnings (EBITDA): 22.7B vs. AMGN (15.9B). NVS has more cash in the bank: 7B vs. AMGN (923M). NVS has less debt than AMGN: NVS (32.6B) vs AMGN (57.4B). NVS has higher revenues than AMGN: NVS (55.2B) vs AMGN (34.9B).
AMGNNVSAMGN / NVS
Capitalization151B250B60%
EBITDA15.9B22.7B70%
Gain YTD12.14736.72133%
P/E Ratio22.9018.72122%
Revenue34.9B55.2B63%
Total Cash923M7B13%
Total Debt57.4B32.6B176%
FUNDAMENTALS RATINGS
AMGN vs NVS: Fundamental Ratings
AMGN
NVS
OUTLOOK RATING
1..100
5726
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
14
Undervalued
PROFIT vs RISK RATING
1..100
4412
SMR RATING
1..100
1329
PRICE GROWTH RATING
1..100
6248
P/E GROWTH RATING
1..100
9780
SEASONALITY SCORE
1..100
n/a65

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AMGN's Valuation (14) in the Biotechnology industry is in the same range as NVS (14) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to NVS’s over the last 12 months.

NVS's Profit vs Risk Rating (12) in the Pharmaceuticals Major industry is in the same range as AMGN (44) in the Biotechnology industry. This means that NVS’s stock grew similarly to AMGN’s over the last 12 months.

AMGN's SMR Rating (13) in the Biotechnology industry is in the same range as NVS (29) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to NVS’s over the last 12 months.

NVS's Price Growth Rating (48) in the Pharmaceuticals Major industry is in the same range as AMGN (62) in the Biotechnology industry. This means that NVS’s stock grew similarly to AMGN’s over the last 12 months.

NVS's P/E Growth Rating (80) in the Pharmaceuticals Major industry is in the same range as AMGN (97) in the Biotechnology industry. This means that NVS’s stock grew similarly to AMGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMGNNVS
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
38%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
54%
Bearish Trend 2 days ago
37%
Momentum
ODDS (%)
Bearish Trend 2 days ago
51%
Bullish Trend 2 days ago
48%
MACD
ODDS (%)
Bearish Trend 2 days ago
50%
Bullish Trend 2 days ago
52%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
56%
Bullish Trend 2 days ago
49%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
49%
Bullish Trend 2 days ago
46%
Advances
ODDS (%)
Bullish Trend 17 days ago
56%
Bullish Trend 2 days ago
49%
Declines
ODDS (%)
Bearish Trend 2 days ago
53%
Bearish Trend about 1 month ago
45%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
63%
Bearish Trend 2 days ago
47%
Aroon
ODDS (%)
Bullish Trend 2 days ago
46%
Bullish Trend 2 days ago
41%
View a ticker or compare two or three
Interact to see
Advertisement
AMGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
KSTR17.470.76
+4.55%
KraneShares SSE STAR Market 50 ETF
TMFM26.110.22
+0.86%
Motley Fool Mid-Cap Growth ETF
IQLT43.420.28
+0.65%
iShares MSCI Intl Quality Factor ETF
LONZ50.850.03
+0.07%
PIMCO Sr Ln Actv ETF
AUGU28.22-0.06
-0.22%
AllianzIM U.S. Equity Buffer15 UncAugETF

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been closely correlated with GSK. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
+0.15%
GSK - NVS
68%
Closely correlated
+0.64%
AZN - NVS
61%
Loosely correlated
-0.40%
PFE - NVS
57%
Loosely correlated
-1.01%
JNJ - NVS
54%
Loosely correlated
+0.43%
SNY - NVS
54%
Loosely correlated
-9.14%
More